🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy jacc.org/doi/10.1016/j.… #JACCHF #HCM #CardioEd JACC Journals

#EHJIMP 🫀 Is anterior mitral valve leaflet length linked to response to mavacamten in HCM? 📐 Shorter length ➡️ Lower dose & Faster response🔬 Could this be a new treatment predictor? 📚 Read more 👉 doi.org/10.1093/ehjimp…

🫀 Managing #HeartFailure across the LV function spectrum? Join the #HFA_ESC webinar: 🎓 Treatment of Heart Failure Across the LV Function Continuum 📌 18 June 2025 📌 18:00–19:00 CET Faculty: Prof Theresa McDonagh , Dr #AntonioBayesGenis & Prof #LarsKober 🔗 Register now:

#EHJCVI 🔄 How is LV-A & RV-PA coupling in HFpEF with high LVEF? ⚠️ Higher risk of death & readmission, but why? 📈 These patients show ↑ left Ees/Ea 🫀 Meanwhile, TAPSE/PASP predicts event-free survival, independent of LVEF 📖 Read more 👉 doi.org/10.1093/ehjci/…

🗞️ DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure #DIGIT_HF Baseline characteristics compared to recent randomized controlled #HF trials European Society of Cardiology Journals Giuseppe Galati Amr Abdin Henry Han Johann Bauersachs BiykemBozkurt bit.ly/3HJQks3

🔍 News from the ALTshock-2 Registry: Does prior beta-blocker (BB) therapy affect outcomes in cardiogenic shock (CS)? 📌 Key Findings from 668 patients (44.8% on BBs): No difference in in-hospital or 48h mortality. ow.ly/APbE50W8T8t EJHF Editor-in-Chief Amr Abdin Giuseppe Galati

In #Altshock2 (n=668), prior beta-blocker (BB) use in cardiogenic shock was linked to: 📍More HF-related CS (43.8% vs. 17.9%) 📍Less cardiac arrest at presentation (20.1% vs. 27.8%) 📍Altered MAP/HR response to inotropes 📍No difference in mortality onlinelibrary.wiley.com/doi/10.1002/eh…

Join us in Minneapolis sans hurricane cancellations. HFSA Devices in Heart Failure Meeting: From Mechanisms to Implementation | HFSA HFSA

CV Risk Modest for Most Cancer Survivors in Large Danish Registry LA McKeown TCTMD Vass Vassiliou tctmd.com/news/cv-risk-m…

🇩🇰 In a large Danish cohort (n=91K cancer survivors vs. 457K controls), 3-year survivors of systemic #cancer therapy had higher 5-year risks of: 📌#VTE (HR 1.50) 📌#HF/#cardiomyopathy (HR 1.08) 📌Myocarditis/pericarditis/endocarditis (HR 1.30) 📌Kidney failure (HR 1.17)

Massachusetts is the #1 state for health care access yet again! But we've still got work to do — especially when Donald Trump and Republicans in Congress are trying to take health care away from thousands of Bay Staters. So, let's get after it.

Right heart catheterization in heart failure: indications, interpretation, and pitfalls academic.oup.com/eurheartj/adva… #CardioEd #EHJ European Society of Cardiology Journals European Society of Cardiology

#CardioMetabolic medicine: the advent of systems cardiology and the new CV generalist? academic.oup.com/eurheartj/adva… ESC President CardioTomLuscher #CardioEd European Society of Cardiology Journals

Current understanding of #HFimpEF jacc.org/doi/abs/10.101… HFSA Circ: Heart Failure Anju Bhardwaj MD FACC Harriette Van Spall, MD MPH 🇨🇦 Nancy Sweitzer MDPhD Alfonso Valle Gregg Fonarow MD British Society for Heart Failure #theFword Carlos G Santos-Gallego, MD Sarah Hudson Giuseppe Galati SABOURETCardiologist Henry Han Julia Seller Diego Segura-Rodríguez @CardioX #CardioTwitter

nejm.org/doi/full/10.10… Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes | New England Journal of Medicine NEJM #ADA2025